Prothena Corp Public Ltd Co
PRTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001559053
In the last 90 days, Prothena Corp Public Ltd Co insiders filed 5 open-market purchases and 2 sales; 187 institutions reported holding it in 13F filings for Q2 2026, worth $462.7M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Prothena Corp Public Ltd Co as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 182
- 0 vs. Q3 2025
- Shares held
- 47.3M
- +4.86M (+11.5%) vs. Q3 2025
- Total value
- $451.6M
- +$37.8M (+9.1%) vs. Q3 2025
- New holders
- 25
- 62 more added
- Sold out
- 25
- 57 more reduced
5 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 187 | $462.7M |
| Q1 2026 | 186 | $459.5M |
| Q4 2025 | 182 | $451.6M |
| Q3 2025 | 187 | $415.8M |
| Q2 2025 | 189 | $253.6M |
| Q1 2025 | 161 | $647.2M |
| Q4 2024 | 171 | $741.3M |
| Q3 2024 | 164 | $855.8M |
| Q2 2024 | 160 | $1.05B |
| Q1 2024 | 169 | $1.33B |
| Q4 2023 | 187 | $1.95B |
| Q3 2023 | 187 | $2.56B |
| Q2 2023 | 196 | $3.54B |
| Q1 2023 | 192 | $2.51B |
| Q4 2022 | 201 | $2.98B |
| Q3 2022 | 183 | $2.69B |
| Q2 2022 | 167 | $1.21B |
| Q1 2022 | 174 | $1.61B |
| Q4 2021 | 196 | $2.12B |
| Q3 2021 | 192 | $2.92B |
| Q2 2021 | 156 | $2.08B |
| Q1 2021 | 146 | $1.00B |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Prothena Corp Public Ltd Co; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −11,660−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −6,949−100.0% | Sold out |
| Manchester Capital Management LLC | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| CVA Family Office, LLC | 0 | $0 | 0.00% | −225−100.0% | Sold out |
| North Capital, Inc. | 0 | $0 | 0.00% | −159−100.0% | Sold out |
| Glen Eagle Advisors, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Truvestments Capital LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |
| Corton Capital Inc. | – | – | – | – | Not filed |
| Point72 (DIFC) Ltd | – | – | – | – | Not filed |
| Point72 Europe (London) LLP | – | – | – | – | Not filed |
| Lowe Wealth Advisors, LLC | – | – | – | – | Not filed |